iShares MSCI Japan Index (NYSEARCA:EWJ) trades flat, Boston Scientific Corporation (NYSE:BSX)

Posted by Lacee Page May 15, 2013 0 Comment 1210 views


iShares MSCI Japan Index (NYSEARCA:EWJ): Tuesday’s trading session saw iShares MSCI Japan Index (NYSEARCA:EWJ) shares headed 0.67% upward. The opening price of $11.88 touched an intraday high of $12.02 per share before setting down to $11.99. A total of around 11.71 million shares were traded in Tuesday’s trading session. This stood below the average volume of 38.09 million, measured over a period of 30 days.

In 2013, the Japanese equity market has proved to be one of the most supercharged one in the international arena.  IShares MSCI Japan Index (NYSEARCA:EWJ) posted  a 20.82% year-to-date gain. The Bank of Japan has been very aggressive with implementation of the new quantitative-easing practices. These are all efforts to catapult the money that is flowing right through their economy. This practice has been in the wake of the Japanese stocks which have been on the rise since 2012 November. EWJ is a non-diversified fund. It seeks to provide results for investment that generally correspond to the yield and price performance of publicly-traded securities, before expenses and fees, in the Japanese market.

Boston Scientific Corporation (NYSE:BSX): Tuesday’s trading session saw Boston Scientific Corporation (NYSE:BSX) shares headed 0.58% upward. The opening price of $8.67 touched an intraday high of $8.74 per share before setting down to $8.70. A total of around 28.73 million shares were traded in Tuesday’s trading session. This was above the average volume of 17.79 million, measured over a period of 30 days.

In the second half of 2013, BSX has full intentions of reversing its losses that it incurred.  It will be launching Watchman. This is a device that is used to treat patients suffering from erratic heart rates. The company hopes to receive approval from the United States Food and Drug Administration, for Watchman. Almost 50% of Boston Scientific Corporation (NYSE:BSX)’s annual revenue comes from the sale of cardiac devices. The FDA application will be filed towards the end of the month and the regulator’s decision is awaited. In the past twelve months Boston Scientific Corporation generated an income of -4535.00 million with sales touching $7.14 billion.


About Lacee Page

Lacee Page is our White House and political campaign reporter. Lacee also covers justice and national law enforcement issues and congressional reporter focusing on the outputs of the legislative process: government spending, agency regulation and congressional oversight. Lacee received a national Edward R. Murrow for spot news award and the regional Associated Press award for best newscast. Lacee attended Riverview High School near Coshocton, and graduated from Ashland College in Ashland, Ohio with a Bachelor of Arts degree in Communications.

View all post by Lacee Page Visit author's website

Write Your Comment